FibroGen, Inc. today announced that the Company has received a Phase II Small Business Innovation Research (SBIR) grant from the National Heart, Lung, and Blood Institute (NHLBI), part of National Institutes of Health (NIH), which provides continued support for the development of FibroGen hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors as therapeutic agents to treat sickle cell disease (SCD).
